ReachMD

ReachMD CME

Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, cardiology, women's health and more. And our CME library is continuously growing, every quarter.

Vizitează neapărat site-ul podcastului și susține-i creatorul: reachmd.com

Autor

ReachMD

Categorie

Science

Site-ul podcastului

reachmd.com

Cel mai nou episod

20 oct. 2026

Unde asculți?

Podcasturi în aplicație Replaio Radio În curând

Podcasturile ajung în curând în aplicație. Instaleaz-o acum și fii primul care descoperă o abordare complet nouă a podcasturilor

Descarcă din Google Play Instalează gratuit Android 10 mil.+ descărcări · nota 4,7+ iOS în curând

Episoade

So You Think You Want a TKI? 04.03.2026

CME credits: 0.75 Valid until: 04-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/So-You-Think-You-Want-a-TKI/54102/ This activity examines the evolving role of tyrosine kinase inhibitors (TKIs) in treating exudative retinal diseases such as wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Experts discuss limitations of current anti-VEGF therapies, emp...

Who Needs a TKI? Identifying the Right Candidates 04.03.2026

CME credits: 0.75 Valid until: 04-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/Who-Needs-a-TKI-Identifying-the-Right-Candidates/54101/ This activity examines the evolving role of tyrosine kinase inhibitors (TKIs) in treating exudative retinal diseases such as wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Experts discuss limitations of current ant...

To Implant or to Inject? 04.03.2026

CME credits: 0.75 Valid until: 04-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/To-Implant-or-to-Inject/54100/ This activity examines the evolving role of tyrosine kinase inhibitors (TKIs) in treating exudative retinal diseases such as wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Experts discuss limitations of current anti-VEGF therapies, emphasi...

TKI: The New TKO for Retinal Diseases 04.03.2026

CME credits: 0.75 Valid until: 04-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/TKI-The-New-TKO-for-Retinal-Diseases/54099/ This activity examines the evolving role of tyrosine kinase inhibitors (TKIs) in treating exudative retinal diseases such as wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Experts discuss limitations of current anti-VEGF thera...

The Struggle Is Real 04.03.2026

CME credits: 0.75 Valid until: 04-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/The-Struggle-Is-Real/54098/ This activity examines the evolving role of tyrosine kinase inhibitors (TKIs) in treating exudative retinal diseases such as wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Experts discuss limitations of current anti-VEGF therapies, emphasizin...

Inside the IgAN Clinic: Shared Decision-Making Into Practice 24.02.2026

CME credits: 0.25 Valid until: 24-02-2027 Claim your CME credit at https://reachmd.com/programs/cme/inside-the-igan-clinic-shared-decision-making-into-practice/26633/ Professor Jonathan Barratt illustrates the integration of shared decision-making in the management of IgA nephropathy while interacting with a real patient with IgAN, highlighting how patient-centered conversations about proteinuria,...

Case-Based Approach: Managing Hyperkalemia in Patients With CKD and Heart Failure 16.02.2026

CME credits: 0.25 Valid until: 16-02-2027 Claim your CME credit at https://reachmd.com/programs/cme/case-based-approach-managing-hyperkalemia-in-patients-with-ckd-and-heart-failure/37617/ Using a real-world patient case, Drs. Ellie Kelepouris and Nihar Desai examine clinical challenges in managing hyperkalemia among patients with chronic kidney disease (CKD) and heart failure (HF). They explore th...

Targeting CKD-aP at the Source: Key Mechanisms and Treatments 16.02.2026

CME credits: 0.25 Valid until: 16-02-2027 Claim your CME credit at https://reachmd.com/programs/cme/targeting-ckd-ap-at-the-source-key-mechanisms-and-treatments/37606/ Drs. Steven Fishbane and Maurizio Gallieni discuss chronic kidney disease-associated pruritus (CKD-aP), a prevalent and under-recognized complication of CKD. They review the epidemiology, pathophysiology, and treatment strategies su...

Safety, Clinical Integration, and the Emerging Fifth Pillar in HF Practice 13.02.2026

CME credits: 0.75 Valid until: 13-02-2027 Claim your CME credit at https://reachmd.com/programs/cme/safety-clinical-integration-and-the-emerging-fifth-pillar-in-hf-practice/54635/ Patients with heart failure with reduced ejection fraction (HFrEF) who have not experienced a recent worsening event pose a major clinical challenge: persistent and under-recognized cardiovascular (CV) risk. Recent findi...

Evidence at a Glance: The Totality of Evidence Impacting Clinical Decision-Making in Patients with HFrEF Without a Recent Worsening Event 13.02.2026

CME credits: 0.75 Valid until: 13-02-2027 Claim your CME credit at https://reachmd.com/programs/cme/evidence-at-a-glance-the-totality-of-evidence-impacting-clinical-decision-making-in-patients-with-hfref-without-a-recent-worsening-event/54634/ Patients with heart failure with reduced ejection fraction (HFrEF) who have not experienced a recent worsening event pose a major clinical challenge: persis...

Do Not Delay: Timing, Triggers, and Identifying the Right Patient for Additional Therapies in HFrEF 13.02.2026

CME credits: 0.75 Valid until: 13-02-2027 Claim your CME credit at https://reachmd.com/programs/cme/do-not-delay-timing-triggers-and-identifying-the-right-patient-for-additional-therapies-in-hfref/54633/ Patients with heart failure with reduced ejection fraction (HFrEF) who have not experienced a recent worsening event pose a major clinical challenge: persistent and under-recognized cardiovascular...

GDMT Is Working Fine, Why Add More Therapies? The Clinical Rationale for Layering Therapies in Patients with HFrEF 13.02.2026

CME credits: 0.75 Valid until: 13-02-2027 Claim your CME credit at https://reachmd.com/programs/cme/gdmt-is-working-fine-why-add-more-therapies-the-clinical-rationale-for-layering-therapies-in-patients-with-hfref/54632/ Patients with heart failure with reduced ejection fraction (HFrEF) who have not experienced a recent worsening event pose a major clinical challenge: persistent and under-recognize...

When GDMT Isn’t Enough: Understanding Residual Risk in Patients with HFrEF 13.02.2026

CME credits: 0.75 Valid until: 13-02-2027 Claim your CME credit at https://reachmd.com/programs/cme/when-gdmt-isnt-enough-understanding-residual-risk-in-patients-with-hfref/51036/ Patients with heart failure with reduced ejection fraction (HFrEF) who have not experienced a recent worsening event pose a major clinical challenge: persistent and under-recognized cardiovascular (CV) risk. Recent findi...

GDMT Is Working Fine, so Why Add More Therapies for Patients With HFrEF? 10.02.2026

CME credits: 0.25 Valid until: 10-02-2027 Claim your CME credit at https://reachmd.com/programs/cme/gdmt-is-working-fine-so-why-add-more-therapies-for-patients-with-hfref/48811/ Contemporary trial data and global registries consistently show that ambulatory patients with heart failure with reduced ejection fraction (HFrEF) who have not experienced a recent worsening event still carry residual risk...

Targeting B7-H3 in ES-SCLC: Advancing Targeted Therapy Through Evidence-Based Innovation and Multidisciplinary Care 10.02.2026

CME credits: 0.25 Valid until: 10-02-2027 Claim your CME credit at https://reachmd.com/programs/cme/targeting-b7-h3-in-es-sclc-advancing-targeted-therapy-through-evidence-based-innovation-and-multidisciplinary-care/36232/ This online educational activity reviews the scientific rationale for B7-H3 as a therapeutic target in extensive-stage small cell lung cancer (ES-SCLC). Tune in for recent clinic...

Test Your Skills and Learn From Experts on Best Practice in Diagnosis and Management of Systemic Mastocytosis 09.02.2026

CME credits: 1.00 Valid until: 08-02-2027 Claim your CME credit at https://reachmd.com/programs/cme/test-your-skills-and-learn-from-experts-on-best-practice-in-diagnosis-and-management-of-systemic-mastocytosis/54694/ On-demand webcast featuring expert-informed best practices for diagnosing and managing patients with systemic mastocytosis (SM) as well as the latest data on new and emerging SM thera...

Early Clues, Lasting Impact: Detecting and Treating Alzheimer’s Disease in Its Earliest Stages 06.02.2026

CME credits: 1.00 Valid until: 05-02-2027 Claim your CME credit at https://reachmd.com/programs/cme/early-clues-lasting-impact-detecting-and-treating-alzheimers-disease-in-its-earliest-stages/56389/ Watch this webcast exploring the evolving landscape of early Alzheimer’s disease (AD) detection and treatment and highlighting the role of cognitive screening, fluid biomarkers, and emerging therapies....

From Late-Line Rescue to Early-Line Option: The Potential for Bispecific Antibodies in Multiple Myeloma 30.01.2026

CME credits: 0.25 Valid until: 30-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/from-late-line-rescue-to-early-line-option-the-potential-for-bispecific-antibodies-in-multiple-myeloma/49264/ This educational activity examines the growing evidence supporting bispecific antibodies in earlier treatment lines of multiple myeloma. Experts discuss the rationale for upstream use of bis...

Advancing Care in HNSCC: Evolving Strategies Across the Disease Continuum 30.01.2026

CME credits: 0.50 Valid until: 30-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/advancing-care-in-hnscc-evolving-strategies-across-the-disease-continuum/48999/ This online educational activity provides clinicians with an in-depth review of the latest findings in head and neck squamous cell carcinoma (HNSCC) from ESMO 2025, highlighting advances in both resectable locally advanc...

Progress in Breast Cancer Care: Translating SABCS Data Into Practice 30.01.2026

CME credits: 0.25 Valid until: 30-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/progress-in-breast-cancer-care-translating-sabcs-data-into-practice/48989/ This online educational activity equips clinicians with up-to-date, practice-changing insights from SABCS 2025. Experts review pivotal data across early-stage and metastatic breast cancer, including advances in HER2- and TROP...

Missing the Window in Ambulatory Patients With HFrEF on GDMT: Strategies for CV Risk Reduction 30.01.2026

CME credits: 0.25 Valid until: 30-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/missing-the-window-in-ambulatory-patients-with-hfref-on-gdmt-strategies-for-cv-risk-reduction/48813/ For ambulatory patients with heart failure with reduced ejection fraction (HFrEF) who have not experienced a recent worsening event, cardiologists continue to face a major clinical challenge: persist...

Personalizing First-Line Therapy for CLL 30.01.2026

CME credits: 0.25 Valid until: 30-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/personalizing-first-line-therapy-for-cll/39262/ This activity focuses on optimizing first-line treatment strategies for patients with chronic lymphocytic leukemia (CLL). Drs. William Wierda and Matthew Davids discuss key distinctions between continuous BTK inhibitor therapy and time-limited venetocl...

Double-Class Refractory CLL in Community Practice: Current and Future Management 30.01.2026

CME credits: 0.25 Valid until: 30-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/double-class-refractory-cll-in-community-practice-current-and-future-management/39261/ Dr. John Byrd discusses current and emerging strategies for managing double-class-refractory chronic lymphocytic leukemia (CLL) in community settings. He emphasizes the importance of distinguishing resistance from...

Navigating Treatment Sequencing After Frontline Treatment Failure in CLL 30.01.2026

CME credits: 0.25 Valid until: 30-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/navigating-treatment-sequencing-after-frontline-treatment-failure-in-cll/39260/ This activity explores treatment sequencing strategies for chronic lymphocytic leukemia (CLL) following frontline therapy failure based on prior therapies, mechanisms of resistance, and minimal residual disease status. D...

It Takes a Village, Part of the Focused Sight Initiative: Quality Improvement Interventions in Retinal Disease 30.01.2026

CME credits: 0.25 Valid until: 30-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/it-takes-a-village-part-of-the-focused-sight-initiative-quality-improvement-interventions-in-retinal-disease/37714/ In this didactic case presentation, Dr. David Eichenbaum discusses an 88-year-old patient with non-central geographic atrophy who received inappropriate bevacizumab treatment due to un...

Ascultă podcastul ReachMD CME în Replaio

Radio și podcasturi într-o singură aplicație - gratuit și fără înregistrare. Instaleaz-o azi și nu rata lansarea

Descarcă din Google Play

Replaio nu este editorul podcasturilor; numele emisiunilor, coperțile și materialul audio aparțin autorilor lor și sunt distribuite prin fluxuri RSS publice